INTRODUCTION

Coronaviruses are responsible for major outbreaks of upper respiratory tract infections in both children and adults. On December 2019, novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. COVID-19 can cause acute and highly virulence pneumonia. It has quickly spread from China to other countries. COVID-19 infection is a major global problem that was documented more than 31 132 906 confirmed cases and approximately 962 008 deaths in the world. On March 12, 2020, WHO declared COVID-19 outbreak a pandemic. Respiratory droplets and person-to-person contact are the most common transmission way. The incubation period of COVID-19 is about 2 weeks. The clinical diagnosis of COVID-19 is confirmed based on polymerase chain reaction technique. The most common symptoms of COVID-19 are fever, dry cough, shortness of breath, and fatigue. Gastrointestinal symptoms, such as diarrhea and nausea, have also been reported in several patients. The overall fatality was reported <2% in patient without underlying disease but higher fatality observed in elderly patients.
and patients with underlying disease (i.e., cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancer). The effective pharmacotherapy can reduce the mortality and morbidity of COVID-19. Studies are recommended various combination therapy with chloroquine, lopinavir/ritonavir (Kaletra), ribavirin (RBV) and tocilizumab (TCZ) for the treatment of COVID-19. On May 2, 2020, FDA approves emergency use of remdesivir (RDV) for COVID-19. One of the most important problems in pharmacotherapy is drug-drug interaction (DDI) which may significantly increase the adverse effects of drug. The present article focuses on reviewing DDIs of chloroquine, RBV, Kaletra, TCZ, and RDV to reduce side effects of COVID-19 treatment.

2 | RIBAVIRIN

Ribavirin (Virazole®), as a broad-spectrum antiviral drug, was approved by FDA in 1986 and administered as an aerosol for infants with respiratory syncytial virus infection. RBV is a nucleos(t)ide analogue polymerase inhibitor which is used for the treatment of hepatitis C virus infection in combination with sofosbuvir and pegylated interferon alpha-2b. The t₁/₂, tₘₐₓ, and bioavailability after a single oral dose of RBV (400 mg) is 1.5 h, 100 h, and 45%–65%, respectively. Combination therapy with RBV and Kiyapning injection (the extraction of Andrographis paniculata) is widely used for inflammation and bronchitis in china. Also, it was used for viral hemorrhagic fever as off-label. RBV is teratogenic and contraindicated in pregnancy (Category X). Also, it is necessary avoiding pregnancy during and 6 months after RBV therapy. Dose adjustment is required in patients with renal and liver impairment. The absorption of RBV occurs in the proximal small intestine by Na⁺-dependent nucleoside (N1) transporters. It is not bound to plasma proteins. The commonly reported adverse effects of RBV were dyspnea (5%), headache (41%–69%), fatigue (25%–58%), anxiety (47%), apnea, hypotension, rash (15%–17%), and conjunctivitis (5%).

An interaction between RBV and warfarin was reported in a 61-year-old man under treatment with interferon, RBV, and warfarin. Also, Peterson et al. evaluate the potential interaction between RBV and warfarin in a 63-year-old man under treatment with long-term warfarin and RBV. A decrease in INR was observed 12 weeks after the initiation of treatment.

RBV may increase the hepatotoxicity of lamivudine and zidovudine may enhance the risk of hematological toxic effects of RBV, specially, and anemia. The mechanism of interaction between RBV and zidovudine is competitive inhibition of intracellular phosphorylation of zidovudine by RBV. The interaction between RBV and abacavir can be associated with competitive inhibition in metabolic pathways, but this interaction is not significant. Mitochondrial toxicity and severe metabolic acidosis syndrome are life-threatening adverse reactions associated with concomitant use of RBV and didanosine that can manifest with symptoms, including pancreatitis, hepatic steatosis, and lactic acidosis. Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in metabolism of azathioprine (AZA) which RBV inhibit this enzyme and enhance the risk of myelotoxicity (i.e., anemia, thrombocytopenia) of AZA. Interaction between RBV and telaprevir was described by Gutierrez-Valencia et al. which may enhance the risk of hematological toxicity by increasing the blood levels of RBV. The mechanism of action of this interaction is inhibition of the proximal tubule transport of RBV by telaprevir.

The significant drug interaction may occur between alpha and beta antagonists with sofosbuvir/RBV regimen during HCV therapy that close monitoring is required. The study conducted by Ramanathan et al. has not demonstrated a pharmacokinetic interaction between tenofovir and RBV. The details of RBV drug interactions are shown in Table 1.

3 | CHLOROQUINE

Chloroquine, a 4-aminoquinolone derivative, is used in the prophylaxis and treatment of uncomplicated malaria. It is also effective in systemic lupus erythematosus and rheumatoid arthritis. The serious side effects associated with chloroquine are retinopathy, otoxicity, and myopathy. Chloroquine can inhibit organic anion transporting polypeptide 1A2 that the inhibition of this transporter is associated with retinopathy. Chloroquine can induce psoriasis in patient as exfoliative erythroderma and pustular psoriasis. The National Health Commission of the People’s Republic of China for tentative treatment of COVID-19 (version 6) recommends chloroquine for the treatment of COVID-19 at doses of 500 mg oral twice daily for 10 days that may shorten the recovery period and improve pulmonary complication findings in imaging. In patients with CrCl <10 ml/min, the recommended dose of chloroquine is 50% normal dose. Chloroquine is completely absorbed after oral administration and it is distributed widely in tissues that include kidney, liver, lung and spleen. About 60% of chloroquine is bound to plasma proteins. It is metabolized by CYP2C8 and CYP3A4 enzymes in the liver and converted into active metabolites (desethylchloroquine and bisdesethylchloroquine). The mechanism of action of chloroquine is inhibition of the polymerization of heme which heme accumulate as toxic agent in the parasite.

The concomitant administration of chloroquine and paracetamol can increase significantly Cₘₐₓ of paracetamol and should be used cautiously. The absorption of chloroquine may decrease by antacids and their administration should be separated by at least 4 h to reduce the risk of drug interaction. A controlled study was performed by Ette et al. for analysis of interaction between cimetidine and chloroquine. The results showed that cimetidine may decrease the metabolism of chloroquine and increase its volume of distribution. The study conducted by Ette et al. showed no significant pharmacokinetic interaction between cimetidine and chloroquine. Therefore, ranitidine is the H₂ blocker of choice for ulcer patients receiving chloroquine. Several clinical studies indicate that chloroquine may increase the metformin-induced cell apoptosis and significantly enhance the metformin-induced inhibition of cancer.
cell proliferation.\textsuperscript{61–63} Chloroquine may increase the risk of hypoglycemic effect of antidiabetic agents.\textsuperscript{64} Chloroquine may reduce the plasma concentration of methotrexate by 20%,\textsuperscript{65} but there is no significant pharmacokinetic interaction between chloroquine and methotrexate. Pukrittayakamee et al.\textsuperscript{66} studied the potential interaction between primaquine and chloroquine in 16 healthy volunteers. Based on the results, chloroquine may increase the serum concentration of primaquine and enhance the risk of QT prolongation. Chloroquine may increase the mean plasma concentration of penicillamine by 34%.\textsuperscript{67} Chloroquine may reduce the plasma concentration of levothyroxine by increasing the catabolism and worsen the control of hypothyroidism.\textsuperscript{68} Chloroquine may reduce the bioavailability and serum concentration of praziquantel by 50% may decrease by non-competitive inhibition of its metabolism by chloroquine.\textsuperscript{69}

Acute dystonic reaction was reported in a 30-year-old woman under treatment with chloroquine and metronidazole.\textsuperscript{70} The pharmacokinetic study do not exhibit drug interaction between chloroquine and azithromycin.\textsuperscript{71} Chloroquine may reduce the therapeutic effect of agalsidase Alfa and Beta.\textsuperscript{72}

Chloroquine may reduce the bioavailability of ampicillin by decreasing the rate of gastric emptying and enhancement of bowel motility.\textsuperscript{73} The co-administration of chloroquine and cyclosporine for malaria prophylaxis or rheumatoid arthritis may elevate cyclosporine levels.\textsuperscript{74–76} Ciprofloxacin is a fluoroquinolone antibiotic with broad antibacterial activity which concomitant use of it with chloroquine may decrease its plasma concentration to below the minimum inhibitory concentration.\textsuperscript{77,78} Patients should be cautioned regarding the concomitant use of chloroquine with tamoxifen because it increases

---

**TABLE 1** The details of RBV drug interactions

| Interacting drugs | The effect of RBV on ADME of other agent | The effect of other agent on ADME of RBV | Consequence | Risk for DDIs | References |
|-------------------|----------------------------------------|------------------------------------------|-------------|--------------|------------|
| **Antiviral (anti-HIV)** | | | | | |
| Didanosine | Mitochondrial toxicity by inhibition of inosine–5′-mono-phosphate | ↑ intracellular inosine monophosphate pool | ↑ serum concentration of the active metabolite(s) of didanosine | X | 35–38 |
| Stavudine | RBV reduces phosphorylation of stavudine | Severe mitochondrial toxicity | ↑ risk of lactic acidosis, pancreatitis, and hepatic steatosis | — | 37 |
| Zidovudine | RBV Inhibits the intracellular phosphorylation of zidovudine | — | ↑ risk of lactic acidosis, pancreatitis, and hepatic steatosis | Avoid combination if possible | D | 29–32 |
| Telaprevir | — | inhibition of the proximal tubule transport of RBV | ↑ plasma creatinine and plasma level of RBV | — | 40,41 |
| Lamivudine | Unknown mechanism | — | RBV may increase the hepatotoxicity of lamivudine | Monitor hepatic enzymes (AST and ALT) | — | 29 |
| Abacavir | Competitive inhibition of phosphorylation | — | ↓ antiviral potency of pegylated interferon plus RBV regimen | RBV increases the toxicity of abacavir | No significant interaction | 33 |
| **Immunosuppressive drug** | | | | | |
| AZA | Inhibition of IMPDH by RBV interferes with AZA metabolism and increase 6-methylthioinosine metabolite | — | ↑ serum concentration of active metabolite(s) of AZA | D | 39 |
| | | | ↑ risk of myelotoxicity (i.e., anemia, thrombocytopenia) of AZA | | | |
| | | | Avoid combination if possible; close monitoring required due to potential for increased hematologic toxicities | | | |
| **Vitamin K antagonists** | | | | | |
| Warfarin | Unknown mechanism | — | ↓ anticoagulant effect of warfarin | C | 27,28 |

Abbreviations: AZA, azathioprine; IMPDH, inosine monophosphate dehydrogenase; RBV, ribavirin.
the risk of retinopathy.\cite{79} The interaction between chloroquine and other QT prolonging agents such as antipsychotic drugs, cisapride, dronedarone, flouxetine, tricyclic antidepressants, citalopram, escitalopram, amiodarone, mefloquine and beta blocker (sotalol) has been life threatening, leading to QT prolongation and ventricular arrhythmias.\cite{80, 81-83} Chloroquine can antagonize the antiepileptic effect of carbamazepine.\cite{81} Chloroquine may inhibit the metabolism of metoprolol by the inhibition of CYP2D6.\cite{83} An interaction between chloroquine and methylene blue was reported by Rengelshausen and co-workers.\cite{84} No pharmacokinetic interaction is observed between chloroquine and imipramine.\cite{85} There is no pharmacokinetic interaction between chloroquine with sulfadoxine and pyrimethamine.\cite{86} Activated charcoal can reduce plasma level of chloroquine by 99% after 5 min.\cite{87} Interaction between indinavir and chloroquine can be enhanced the antimalarial effect of chloroquine against chloroquine-resistant line and chloroquine-sensitive line P. chabaudi.\cite{88} There is no clinically significant interaction between tafenoquine and chloroquine.\cite{89} The details of chloroquine drug interactions are summarized in Table 2.

## 4 | LOPINAVIR/ RITONAVIR

Kaletra\cite{90} approved in 2000 for widely used in combination with other antiretroviral compounds to treat HIV-1 in children 14 days of age and older, also in adults.\cite{90} Lopinavir binds to the HIV-protease site of activity and prevents the formation of functional proteins required for viral pathogenesis, resulting in non-infectious and immature viruses.\cite{91} Ritonavir inhibits lopinavir metabolism via CYP3A4 and boosts the plasma levels of lopinavir. Furthermore, when co-formulated with ritonavir that improves the bioavailability of lopinavir. So it can be said, the significant antiretroviral effects of Kaletra are due to lopinavir.\cite{92} Kaletra binds to plasma proteins approximately 98%–99%, and elimination half-life after a single-dose administration is nearly 2–3 h. Kaletra is mainly eliminated with feces and is <2% in the urine.\cite{90, 93} Kaletra is classified as category C in pregnancy and only prescribed when the beneficial impacts of this on the fetus exceed from harmful effects.\cite{90} The possible adverse effects of Kaletra are hyperglycemia (≤5%), abdominal pain (1%–11%), pancreatitis (≤2%), diarrhea (7%–28%), lipid elevation (3%–39%), nausea (5%–16%), and vomiting (adults 2%–7%; children 21%), and QT prolongation (≤2%). Kaletra could be recommended in high-risk patients (old patients or patients with underlying disorders) with COVID-19 as an adjunctive medication based on the evidence of in vitro studies. It was prescribed 400/100 mg twice daily for 14 days.\cite{94, 95} Nevertheless, recently the results of many studies in the administration of Kaletra in COVID-19 patients have been controversial. Such as the Coa et al. randomized controlled open-label trial at 199 hospitalized patients with COVID-19 (99 patients receiving Kaletra and 100 patients receiving standard care for 14 days) demonstrated that the use of Kaletra alone has not advantageous for clinical improvement in severe COVID-19.\cite{96} A randomized controlled trial in patients with severe COVID-19 in Guangzhou, China, was performed to evaluate the efficacy and safety of Kaletra or Arbidol in comparison with the control group and showed the use of Kaletra or Arbidol as monotherapy may not improve clinical outcomes instead increases adverse effects in hospitalized patients. Accordingly, more extensive clinical trials may be required to estimate the efficacy of Kaletra in patients with severe COVID-19.\cite{97, 98} Ritonavir is potent inhibitor of the CYP3A4 and moderate inhibitor of P-glycoprotein, CYP2D6, OTAP1B1, and OTAP1B3. Also, induced the hepatic enzyme’s CYP1A2, CYP2B6, and UGT1A1. Lopinavir is inhibiting CYP3A4 and CYP2D6.\cite{99, 100} Thus, Kaletra will be many interactions with other groups of medications, and it is crucial to consider these interactions in pharmacotherapy. These interactions with details were described in Table 3.

## 5 | TOCILIZUMAB

Tocilizumab (Actemra\textsuperscript{8}) is a recombinant humanized monoclonal antibody against the soluble and membrane receptors of IL-6. It mainly used to treatment of autoimmune diseases such as rheumatoid arthritis and polyarticular juvenile idiopathic arthritis.\cite{117} The mechanism of action of TCZ is inhibition of IL-6 receptors, which stimulates regulatory B cells, and reduces the expression of inflammatory cytokines and chemokine genes. As a result, it increases the expression of synovial fluid proteins.\cite{118} Elimination of TCZ depends on the serum concentration of the drug and is associated with the degree of IL-6 receptor saturation. The non-linear pathway is prominent at low serum concentrations. At high concentrations, after the receptors are completely saturated, the non-specific linear elimination pathway will predominate. Besides, higher sustained target saturation occurs with infused doses of 8 mg/kg every 4 weeks (compared with 4 mg/kg), which leads to a longer half-life and reduced elimination. Extended exposure to high concentrations of the drug may enhance the responses.\cite{117, 119, 120} The volume of distribution of TCZ is restricted to serum compartment. Its elimination rate is relatively slow.\cite{121} The efficacy of the intravenous and subcutaneous formulations of TCZ have been studied and appear to be similar.\cite{117, 118} Common adverse effects associated with the use of TCZ are gastrointestinal problems, and increased risk of infection. Also, transient neutropenia, elevated hepatic enzymes, and increased total and LDL cholesterol may occur in patients receiving TCZ.\cite{117, 122} Other side effects that happen frequently are hypertension and headaches.\cite{123} TCZ should not use during pregnancy because adequate evidence is not available for this population. Animal studies display at over human doses (>100 folds) may enhance the inevitable abortion slightly. Analysis of retrospective global results demonstrates that women who have an exposure to this medication for a short time in the first trimester or before conception do not experience a notable risk of anomalies.\cite{118, 124} Studies show that IL-6 is one of the key inflammatory cytokines in the development of SARS-induced inflammation, which raises the insufficiency of alveolar blood-gas exchange and eventually leads to lung fibrosis and organ failure.\cite{125, 126} In a study performed on 21 patients with critical
| Interacting drugs | The effect of chloroquine on ADME of other agent | The effect of other agent on ADME of chloroquine | Consequence | Risk for DDIs | References |
|------------------|-----------------------------------------------|-----------------------------------------------|-------------|--------------|------------|
| Paracetamol      | Chloroquine can increase significantly $C_{\text{max}}$ of paracetamol | —                                            | $\uparrow$ paracetamol plasma concentration | —            | 56         |
|                  |                                               |                                               | Avoid co-administration                      |              |            |
| Antacids         | —                                            | The absorption of chloroquine is reduced by antacids | Should be separated by at least 4 h       | D            | 57,58      |
|                  |                                               |                                               | Administration should be separated by at least 4 h |              |            |
| Cimetidine       | —                                            | Cimetidine inhibits the metabolism and clearance of chloroquine | May increase the serum concentration of Chloroquine | C            | 59         |
|                  |                                               |                                               | Consider ranitidine as an alternative or take cimetidine at least 2 h after chloroquine |              |            |
|                  |                                               |                                               | Consider another antiulcer medication ranitidine or take cimetidine at least 2 h after CQ  |              |            |
| Antidiabetic agent | Chloroquine increases insulin sensitivity | —                                            | May increase the risk of hypoglycemic effect of antidiabetic agents (severe hypoglycemia) | C            | 64         |
|                  |                                               |                                               | Check blood sugar level and reduce daily dose of insulin |              |            |
| Immunosuppressive drug |                               |                                               |                           |              |            |
| Methotrexate     | Chloroquine may reduce the bioavailability of methotrexate | —                                            | $\downarrow$ maximum plasma levels of methotrexate about 20% and $\downarrow$ it’s AUC about 28% | Not significant | 65         |
| Cyclosporine     | $\downarrow$ metabolism of cyclosporine by competitive inhibition (inhibition of P-gp activity by chloroquine) | —                                            | $\uparrow$ cyclosporine levels Monitor renal function weekly and cyclosporine levels for toxicity | D            | 74–76      |
| Primaquine       | Chloroquine may enhance the serum levels of primaquine | —                                            | $\uparrow$ risk of QT interval prolongation Caution with drugs that affect cardiac conduction | C            | 66         |
| Penicillamine    | Chloroquine increases the peak plasma levels of penicillamine about 34% | —                                            | Severe hematologic and renal toxicity Monitor acute toxicity | —            | 67         |
| Levothyroxine    | —                                            | Chloroquine may increase the catabolism of levothyroxine by enzymatic induction | Chloroquine may decrease the plasma concentration of levothyroxine Poorly controlled hypothyroidism Monitor TSH levels when beginning and discontinuing chloroquine | —            | 68         |
| Praziquantel     | —                                            | Chloroquine may decrease the bioavailability of praziquantel | Chloroquine may reduce the serum concentration of praziquantel about 50% An increased dosage of PZQ should be considered | C            | 69         |
| Agalsidase-alfa and agalsidase-beta | —                                            | Chloroquine inhibits intracellular $\alpha$-galactosidase activity | $\downarrow$ therapeutic effect of agalsidase-alfa and agalsidase-beta Agalsidase $\alpha$/$\beta$ should not be used with chloroquine | X            | 72         |

(Continues)
TABLE 2 (Continued)

| Interacting drugs | The effect of chloroquine on ADME of other agent | The effect of other agent on ADME of chloroquine | Consequence | Risk for DDIs | References |
|-------------------|-----------------------------------------------|-----------------------------------------------|-------------|--------------|------------|
| Antibiotics       |                                               |                                               |             |              |            |
| Metronidazole     | Pharmacodynamic interaction                   | —                                             | Metronidazole increase the risk of dystonic reaction of chloroquine | —           | 70         |
| Ampicillin        | Chloroquine may decrease the rate of gastric emptying and gut motility | —                                             | ↓ absorption, bioavailability and serum concentration of ampicillin | D           | 73         |
| Ciprofloxacin     | Chloroquine may increase urinary excretion of Ciprofloxacin | —                                             | The concentration of ciprofloxacin may decrease to below the minimum inhibitory concentration for Plasmodium falciparum Avoid co-administration | —           | 77,78      |
| Tamoxifen         | Mechanism is unclear, although tamoxifen is a retinal toxin (additive effect with chloroquine) | —                                             | Tamoxifen may enhance the retinopathy of chloroquine. Monitor retinopathy regularly. | C           | 79         |
| QT-prolonging agent |                                               |                                               |             |              |            |
| Amisulpride       | Additive effect with QT prolongative agent    | —                                             | The concomitant use can increase the risk of QT-interval prolongation. Monitor electrolytes level and ECG regularly. | C           | 80–82      |
| Domperidone       |                                               |                                               |             | D           |            |
| Fexinidazole      |                                               |                                               |             | X           |            |
| Haloperidol       |                                               |                                               |             | C           |            |
| Ondansetron       |                                               |                                               |             | C           |            |
| Pentamidine       |                                               |                                               |             | X           |            |
| Pimozide          |                                               |                                               |             | X           |            |
| Mefloquine        |                                               |                                               |             | C           |            |
| QT-prolonging antidepressants such as citalopram, escitalopram, fluoxetine |                                               |                                               |             |              |            |
| Carbamazepine     | Chloroquine can antagonize the antiepileptic effects of carbamazepine. | —                                             | Chloroquine decrease seizure threshold Increased dose of carbamazepine | —           | 81         |
| Metoprolol        | Chloroquine inhibits the metabolism of metoprolol | —                                             | ↑ the plasma level of metoprolol (AUC about 65% and peak plasma level 72%) Reduce daily dose of metoprolol | —           | 83         |
| Methylene blue    | —                                             | Methylene blue may decrease the AUC of chloroquine (about 20%) | ↓ the plasma level of chloroquine | —           | 84         |
| Activated charcoal | The absorption of chloroquine may be diminished by activated charcoal | —                                             | The effect of chloroquine may diminish in the presence of activated charcoal Avoid co-administration | —           | 87         |
| Indinavir         | —                                             | Synergistic activity                          | Indinavir can be increased the antimalarial activity of chloroquine | —           | 88         |
| Interacting drugs                  | The effect of kaletra on ADME of other agent                                                                 | The effect of other agent on ADME of kaletra | Consequence                                                                 | Risk for DDIs | References       |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------------------------|---------------|-----------------|
| HMG-CoA reductase inhibitors (statins) |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Atorvastatin                       | Atorvastatin is a CYP3A4 substrate and kaletra will increase the concentration by 5.9 times in the concomitant use | —                                          | Avoid concurrent use or utilize alternative medicine. When the concomitant use is unavoidable, the dose of atorvastatin should not exceed 20 mg per day. Besides the signs of toxicity should be carefully evaluated | D             | 100.101         |
| Lovastatin                         | Simultaneous use with Kaletra will increase plasma concentration and risk of toxicity                                                            | —                                          | Contraindicated                                                            | X             | 100.102         |
| Pravastatin                        | Kaletra can increase the plasma concentration of pravastatin to near 33% during concomitant use (due to inhibiting of OTAP1B1)                  | —                                          | Use with caution                                                           | —             | 100.101         |
| Rosuvastatin                       | Kaletra increases the effects of rosuvastatin by reduction in metabolism                                                                      | —                                          | Avoid concomitant use or utilize alternative medication                    | D             | 100.102         |
| Simvastatin                        | The liver enzymes are inhibiting through Kaletra. Thus, systemic exposure of simvastatin and the risk of rhabdomyolysis increase                  | —                                          | Contraindicated                                                            | X             | 100.103         |
| Antimalarial agents                |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Atovaquone                         | The plasma concentration of Atovaquone decreases to 74% during simultaneous use with Kaletra                                                      | —                                          | Should be monitoring closely                                               | C             | 100            |
| Proguanil                          | The plasma level and AUC of proguanil reduces to 40% when concurrent use with Kaletra (due to inducing of CYP2C19 enzyme by Kaletra)             | —                                          |                                                                            |               |                 |
| Quinine                            | The plasma level of quinine increase when concomitant use with ritonavir and its dose should be decreased by 50%. On the other hand, lopinavir and quinine prolonged the QT interval | —                                          | Contraindicated                                                            | X             | 100.104.105    |
| PDE-5 inhibitors                   |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Sildenafil                          | Kaletra will increase the effect of these medications by affecting hepatic/intestinal enzyme CYP3A4 metabolism                                | —                                          | Start as the lower dose when to use simultaneously. For example, the start dose of sildenafil should not be more than 25 mg in 48 h | D             | 102.106         |
| Tadalafil                          |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Vardenafil                         |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Antifungal agents                  |                                                                                                                                                   |                                            |                                                                            |               |                 |
| Posaconazole                       | Ritonavir increases plasma concentrations of Posaconazole by P-glycoprotein efflux transporter                                                   | Posaconazole can increase the level of Kaletra by affecting CYP3A4 metabolism | Should be used with caution                                               | C             | 100.107         |
| Voriconazole                       | Ritonavir reduces plasma levels of voriconazole by boosting metabolism                                                                        | Voriconazole can raise the concentration of Kaletra by affecting CYP3A4 metabolism | Contraindicated                                                            | X             |                 |

(Continues)
| Interacting drugs | The effect of kaletra on ADME of other agent | The effect of other agent on ADME of kaletra | Consequence | Risk for DDIs | References |
|-------------------|--------------------------------------------|---------------------------------------------|-------------|----------------|------------|
| Eplerenone        | Plasma level of eplerenone increases due to the effect of ritonavir on CYP3A4 | — | Contraindicated | X | 101 |
| Calcium channel blockers | | | | | |
| Amlodipine        | The effect of Amlodipine increases in concomitant use with Kaletra via interacting with CYP3A4 | — | Should be used with caution | C | 100,101,108 |
| Non-dihydropyridine | All of them are metabolized by CYP3A4. So, the elevated serum concentration of CCBs through PIs may increase the risk of AV nodal blockade and PR prolongation | — | Avoid concomitant use or use by monitoring of CCB toxicity | D | |
| Digoxin           | Ritonavir increases the level of digoxin about 29% via P-glycoprotein efflux transporter also by reducing renal and hepatic clearance | — | The effects of digoxin should be monitored carefully in concurrent use with Kaletra. Also, digoxin can prolong the PR interval in combination with PIs | D | 100,101 |
| Alfa 1 blockers   | The systemic levels of these drugs increase in concurrent use with Kaletra as they are CYP3A4 substrates | — | The plasma level should be exactly titrated | — | 99,101,108 |
| Doxazosin         | The plasma level of Alfuzosin increases due to the effect of ritonavir on CYP3A4. Also, the QT interval will increase with both lopinavir and alfuzosin | — | Contraindicated | X | |
| Alfuzosin         | — | — | — | — | |
| Tamsulosin        | Kaletra will increase levels of tamsulosin by affecting CYP3A4 and 2D6 metabolism | — | — | — | |
| Beta blockers     | Ritonavir can increase the effect of these medications in concomitant use by affecting CYP2D6 metabolism. As a result, bradycardia and PR prolongation have been reported | — | Using atenolol instead of these medications is recommended. | — | 99,101 |
| Anti-arrhythmic medications | All of these drugs are substrates for hepatic enzymes (CYP3A4 and 2D6) metabolism. Their plasma levels are increased by the use of Kaletra concurrently. Thus, they may cause cardiac toxicity and many anomalies in the ECG, such as prolonged QT interval | — | Co-administration of these medications with Kaletra is contraindicated | X | 99,101,108 |
| Mexiletine        | — | — | — | — | |
| Anticoagulants    | Kaletra increases the effects of apixaban by affecting CYP3A4 metabolism | — | Avoid concomitant use or utilize alternative medication | D | 99,101 |

(Continues)
## Interacting drugs

### Dabigatran
- Kaletra will increase the plasma concentration of dabigatran and edoxaban by P-glycoprotein efflux transporter
- Consequence: Although a recent case report illustrated that the safe administration of dabigatran with Kaletra by planning consumption to be 1 h apart, co-administration should be with caution
- Risk for DDI: —
- References: 100,101,109

### Edoxaban
- Kaletra will increase the levels of rivaroxaban via affecting CYP3A4 metabolism
- Consequence: This combination may increase the risk of bleeding. So, avoid concomitant use
- Risk for DDI: X
- References: 99,101

### Rivaroxaban
- Ritonavir decreases the metabolism of R-warfarin by inhibiting the CYP3A4 enzyme. On the other hand, it increases the metabolism of warfarin due to the stimulation of CYP 2D9 and CYP 1A4 enzymes. In general, it will raise the need for warfarin by 2–3 folds
- Consequence: Accordingly, INR should be checked routinely during concurrent use with Kaletra
- Risk for DDI: C
- References: 99,101,110

### Warfarin
- Dabigatran Kaletra will increase the plasma concentration of dabigatran and edoxaban by P-glycoprotein efflux transporter
- —
- References: —

### Antidiabetic agents
- Nateglinide
  - Kaletra decreases effects of nateglinide
  - Consequence: Should be monitoring closely.
  - Risk for DDI: —
  - References: 99,111

- Repaglinide
  - Kaletra will increase the effects of these medications by affecting CYP3A4 metabolism
  - Consequence: Should be used with caution.
  - Risk for DDI: C
  - References: —

- Saxagliptin
  - Limit the dose to 2.5 mg/day while co-administered by strong CYP3A4 inhibitors
  - Consequence: —
  - Risk for DDI: D
  - References: —

### Corticosteroids
- Budesonide (Nasal & Inhaler)
  - Kaletra increases the effect of these medications by affecting hepatic enzyme's metabolism. Thus, in concomitant use of corticosteroids with Kaletra may cause Cushing syndrome
  - Consequence: Concurrent use does not suggest.
  - Risk for DDI: C
  - References: 99,100,112

- Fluticasone (Nasal)
  - Beclomethasone or Flunisolide could be replaced for these drugs
  - Risk for DDI: X
  - References: —

- Triamcinolone
  - Risk for DDI: C
  - References: —

### Disulfiram
- Disulfiram may enhance the toxicity of Kaletra through inhibition of aldehyde dehydrogenase
- Consequence: Contraindicated
- Risk for DDI: X
- References: 106

### Colchicine
- The plasma level of Colchicine will be increased if used with Kaletra concurrently
- Consequence: This combination is contraindicated in cases with hepatic or renal impairment
- Risk for DDI: D
- References: 99

### Antipsychotic agents
- Lurasidone
  - Kaletra increases the effect of Lurasidone by affecting CYP3A4 metabolism
  - Consequence: Co-administration of this drug and strong CYP3A4a inhibitors are contraindicated
  - Risk for DDI: X
  - References: 106

- Olanzapine
  - Kaletra will increase the effect of Olanzapine by affecting CYP3A4 metabolism
  - Consequence: Should be used with caution
  - Risk for DDI: C
  - References: —

- Quetiapine
  - The plasma concentration of Quetiapine will increase when used concomitantly with ritonavir. Additionally, both Kaletra and Quetiapine are prolonging the QT interval
  - Consequence: Its dose should be reduced to one sixth of the standard dose
  - Risk for DDI: D
  - References: —

(Continues)
TABLE 3 (Continued)

| Interacting drugs | The effect of kaletra on ADME of other agent | The effect of other agent on ADME of kaletra | Consequence | Risk for DDIs | References |
|--------------------|---------------------------------------------|---------------------------------------------|-------------|--------------|------------|
| **Analgesics**     |                                             |                                             |             |              |            |
| Buprenorphine      | Kaletra may increase the serum level of Buprenorphine by affecting CYP3A4 metabolism | Should be monitored closely               | C           | 100,106      |            |
| Codeine            | Kaletra decreases the serum concentration of Codeine by affecting CYP2D6 metabolism | —                                          | 99          |              |            |
| Methadone          | Due to the effect of Kaletra on liver enzymes, the AUC significantly decreased during concomitant use with Kaletra. It also prolongs the QT interval | —                                          | 99,100,106  |              |            |
| Oxycodone          | The plasma concentration of oxycodone increases by 2–3 fold with Kaletra, by affecting CYP3A4 & 2D6 metabolisms | —                                          | 99,100,113  |              |            |
| Tramadol           | The plasma level of tramadol increases with Kaletra because metabolized by CYP3A4 | Should be monitoring closely               | C           | 99           |            |
| **Anticonvulsants**|                                             |                                             |             |              |            |
| Carbamazepine      | When used concomitantly with ritonavir compounds, carbamazepine may reach toxic levels | Carbamazepine decreases the level of Kaletra by affecting CYP3A4 metabolism | Accordingly, close monitoring and dose adjustment will be needed | D           | 100,106    |
| Lamotrigine        | The half-life of lamotrigine reduces in co-administration with Kaletra | —                                          | Its dose should be increased by 50% | D           | 106        |
| Phenytoin          | —                                          | Phenytoin will decrease the level of Kaletra to 33% by stimulation of hepatic enzymes (CYP3A4 & P-glycoprotein) metabolism | The dose of Kaletra should increase at the concurrent use | D           | 100        |
| Valproate (Divalproex) | Kaletra may reduce the serum level of Divalproex | —                                          | Should be monitoring closely | C           | 106        |
| **Antidepressants**|                                             |                                             |             |              |            |
| Bupropion          | Kaletra decreases the serum concentration of bupropion to 57% by inducing CYP2B6 metabolism | —                                          | Should be monitoring closely | C           | 99,106     |
| Citalopram         | Kaletra increases levels of citalopram & escitalopram by affecting CYP3A4 metabolism. So the risk of serotonin syndrome and QT prolongation increases | —                                          | The monitoring of ECG recommended when using Kaletra concurrently. Also, the dose of these drugs should not exceed 20 mg daily for above 60 years | —           | 99,100     |
| Escitalopram       | —                                          | —                                          | —           | —            | 99,100     |
| Fluoxetine         | Ritonavir increases the effect of fluoxetine by affecting CYP2D6 metabolism | —                                          | —           | —            | 99,100     |

(Continues)
## TABLE 3 (Continued)

| Interacting drugs | The effect of kaletra on ADME of other agent | The effect of other agent on ADME of kaletra | Consequence | Risk for DDIs | References |
|-------------------|-------------------------------------------|-------------------------------------------|-------------|--------------|------------|
| **Interacting drugs** | **The effect of kaletra on ADME of other agent** | **The effect of other agent on ADME of kaletra** | **Consequence** | **Risk for DDIs** | **References** |
| **Mirtazapine** | Kaletra increases serum concentration of mirtazapine by affecting CYP3A4 metabolism | — | If concurrent use with Kaletra, administration of the minimum effective dose should be considered | C | 106 |
| **Nefazodone** | Nefazodone metabolized by CYP3A4. So, the plasma level and adverse effects of nefazodone may increase in using with Kaletra concurrently | — | As a result, toxic effects must be monitored closely. The maximum dose should be limited to 50–100 mg/day | D | 106 |
| **Trazodone** | Kaletra may increase the level of trazodone to 240% by inhibiting CYP3A4 metabolism | — | Using lower initial dose and monitoring CNS & cardiovascular effects should be considered when combined with Kaletra | D | 99,106 |
| **Natural products** | **Red yeast rice** | Kaletra increases the effect of Red Yeast Rice by inhibiting CYP3A4 metabolism. As a result, it may increase the risk of rhabdomyolysis or myopathy and creatine kinase levels | — | Contraindicated | X | 100 |
| **St John’s Wort** | — | St John’s Wort will decrease the effect of Kaletra by affecting CYP3A4 metabolism and P-glycoprotein efflux transporter | — | Contraindicated | X | 100.106 |
| **Sedative-hypnotics & anxiolytics** | **Alprazolam** | Kaletra will increase the effect of these medications by inhibiting CYP3A4 metabolism | — | Monitoring for increased toxic effects of alprazolam and starting to be careful prescribing if combined with Kaletra | D | 106 |
| **Buspirone** | — | It should be monitored closely for side effects | — | — | D | 106 |
| **Midazolam** | — | Contraindicated | — | — | X | 106.114 |
| **Triazolam** | — | Co-administration with PIs increases the hypnotic effects and psychomotor disorders. Therefore, this combination is contraindicated | — | — | X | 106 |
| **Zolpidem** | — | Should be monitoring closely | — | — | C | 99 |
| **Antibacterials** | **Salmeterol** | Kaletra may increase the effect of salmeterol by inhibiting CYP3A4 metabolism | — | Simultaneous use contraindicated due to increased cardiac complications | X | 99 |
| **Rifabutin** | Ritonavir may increase the serum concentration of rifabutin by reducing metabolism | Furthermore, rifabutin may decrease the effect of Kaletra by affecting CYP3A4 metabolism | Should be dose modification and closely monitoring considered | D | 100 |

(Continues)
COVID-19, TCZ was combined at a dose of 400 mg intravenously with common drug regimens. Clinical data demonstrate that the symptoms, variations in CT-opacity, and hypoxemia rapidly improved after the TCZ administration. No side effects or lung infections reported during treatment. Accordingly, TCZ could be recommended as an effective medication for severe cases of COVID-19.\(^\text{127}\) In vitro studies explain that TCZ inhibits the downregulation of CYP (CYP3A4, CYP2C9, CYP2C19, and CYP1A2) enzymes by IL-6, which may interact with medications that are a substrate for these enzymes. Therefore, when taken concomitantly with medicines that have a narrow therapeutic window such as warfarin, phenprocoumon, theophylline, cyclosporine, and phenytoin should be considered particular care. Also, due to the long half-life of TCZ, it may be required monitoring of these interactions for 1–2 months after discontinuation of TCZ.\(^\text{117,128}\) One study reported three cases of mesenteric arterial thrombosis associated with the application of TCZ in patients who were under previous anticoagulant therapy. The use of TCZ may stimulate the metabolism of anticoagulants by reducing the inhibitory effects of IL-6 on CYP450 enzymes. Rivaroxaban is a substrate of CYP3A4 and P-glycoprotein, and warfarin is a substrate of the CYP2B6, CYP3A4, CYP2C19, and CYP2C9 enzymes which used simultaneously with TCZ reduces the plasma concentration of these anticoagulants. So, this can lead to thrombosis. P-glycoprotein restricts the absorption of dabigatran. Inhibition of IL-6 by TCZ, modifying P-glycoprotein function, thereby reducing the bioavailability of dabigatran etexilate. Accordingly, concurrent use with TCZ reduces the anticoagulant effects of dabigatran and helps to progress thrombosis.\(^\text{129}\) Pharmaceutical interactions studies show that simvastatin plasma levels (substrate CYP3A4) decrease when administered concurrently with TCZ. In other words, 1 week after administration of 10 mg/kg single dose of TCZ, the AUC of simvastatin reduces by 57% (2.3-fold reduction).\(^\text{121,130}\) The combination of TCZ with TNF-α inhibitors such as adalimumab, due to their synergistic effect on modulating the immune responses, concerns about serious infections and injection site reactions increases.\(^\text{118,131}\) Also, a combination of omeprazole and TCZ decreases omeprazole AUC by increased CYP2C19 activity.\(^\text{121}\) The details of TCZ drug interactions are summarized in Table 4.

| Interacting drugs | The effect of kaletra on ADME of other agent | The effect of other agent on ADME of kaletra | Consequence | Risk for DDIs | References |
|-------------------|---------------------------------------------|---------------------------------------------|-------------|-------------|------------|
| Rifampin          | —                                           | Rifampin may decrease the level of Kaletra by affecting CYP3A4 metabolism and P-glycoprotein efflux transporter. This combination may increase the risk of toxicity specifically may result in hepatocellular toxicity | Contraindicated | X | 100 |
| Ergotamine        | Ritonavir increases level of ergotamine by decreasing CYP3A4 metabolism | —                                           | Contraindicated | X | 100 |
| Dronabinol        | Dronabinol is a CYP3A4 substrate and Kaletra may increase the level of dronabinol by inhibiting CYP3A4 metabolism | —                                           | Should be monitoring closely | C | 99 |

**Antineoplastics**
- **Bortezomib**
- **Cyclophosphamide**
- **Docetaxel**
- **Doxorubicin**
- **Erlotinib**
- **Imatinib**
- **Irinotecan**
- **Sunitinib**
- **Vinblastine**
- **Vincristine**
- **Vinorelbine**

These medications are often CYP3A4, CYP2B6, and P-glycoprotein substrates. As a result, Kaletra may increase the plasma concentration of antineoplastic agents by inhibiting these hepatic enzyme’s metabolism.

| Interacting drugs | Consequence | Risk for DDIs | References |
|-------------------|-------------|---------------|------------|
| **Antineoplastics** | — | — | 99,115,116 |
| **Bortezomib** | — | — | C |
| **Cyclophosphamide** | — | — | C |
| **Docetaxel** | — | — | D |
| **Doxorubicin** | — | — | D |
| **Erlotinib** | — | — | D |
| **Imatinib** | — | — | C |
| **Irinotecan** | — | — | X |
| **Sunitinib** | — | — | D |
| **Vinblastine** | — | — | D |
| **Vincristine** | — | — | D |
| **Vinorelbine** | — | — | C |
Remdesivir (by pharmaceutical code: GS-5734) is an antiviral medication. In 2014, the effects of RDV on Ebola virus was evaluated by Eastman et al. in West Africa. RDV is a prodrug of nucleoside analogous that metabolized via intracellular anabolic kinase to active nucleoside triphosphate metabolite (GS-443902) in tissues. It inhibits the activity of RNA polymerase and prevents duplication of virus in the infectious cycle. In 2017, the antiviral effects of RDV on the SARS and MERS viruses were evaluated and show effective results against these viruses and other coronaviruses. With the advent of COVID-19, hopes for the efficacy of RDV increased again. Some studies, such as Wang et al., have shown that the RDV has a notable effect on the restriction of viral infection in cultured cells in the laboratory. Besides, in vitro and pre-clinical in-vivo animal models also support the effects of RDV against SARS-CoV-2. RDV is produced as a lyophilized powder and is administered as an IV infusion over 30 min to achieve high concentrations of active intracellular metabolite. Based on pharmacokinetic data, the plasma half-life of RDV produg is short ($t_{1/2} = 0.39$ h) when prescribed at a dose of 100 mg/day by a loading dose of 200 mg for a maximum of 10 days in non-human primates. However, levels of intracellular triphosphate form remain in the human body for a longer time.
patients in the United States include vomiting, rectal bleeding without other symptoms, nausea and gastroparesis. Also, these patients experience high levels of aminotransferase during 1–5 days after the initiation of RDV.94 The most prominent side effect of RDV appears to increase liver enzymes (ALT & AST). For this reason, the evaluating level of liver enzymes before starting treatment with RDV is recommended. If the ALT level was more (>5 fold) than the normal upper limit, RDV must hold or not initiate. Additionally, RDV should not be used in glomerular filtration rate <30 ml/min.132 Available information for RDV during pregnancy is inadequate. Only one randomized trial investigated the effects of RDV in six pregnant women during the Ebola epidemic and any side effects not reported.139 So far, no contraindications have identified for this medication; except concurrent use with other proven hepatotoxic drugs such as rifampicin. Based on the rapid pharmacokinetics of distribution, metabolism, and excretion of RDV, the probability of clinical interactions seems low (dose monitoring recommended in concomitant use with methimazole).132 No interaction found between immunosuppressants and RDV. Nevertheless, when using with RDV concomitantly monitoring levels of immunosuppressive medications suggested.133 RDV at in vitro studies appears to be a substrate for CYP2C8, CYP2D6, and CYP3A4 enzymes. However, on in vivo conditions, the metabolism of RDV is following the action of hydrolase, which indicates that potential clinical interactions with inhibitors or inducers of CYP enzymes are unlikely. For example, the concurrent use of RDV with carbamazepine could decrease the levels of RDV significantly, whereas this interaction not reported experimentally. Moreover, according to the weak role of hepatic enzymes in RDV metabolism, the probability of this interaction will be much lower. In general, RDV drug interactions are not verified carefully. Accordingly, possible interactions may help to discover potential clinical drug interactions associated with RDV.134 Generally, the evidence about the safety and efficacy of RDV in the treatment of COVID-19 is limited. Due to the ambiguous effects of RDV against COVID-19, it has not been obtained definitive approval from FDA. Only ordered for patients in clinical trials, emergency states, or compassionate use.135,140,141 These interactions with details were described in Table 4.

7 | CONCLUSION

COVID-19 is currently a global and life-threatening issue and there is no FDA-approved vaccine for prevention of it. FDA approves emergency use of RDV for COVID-19. Based on the clinical data, pharmacotherapy including chloroquine, Kaletra, RBV, and TCZ is recommended for the treatment of COVID-19. Patients with underlying disease have a higher risk for COVID-19 infection because often need to be treated with multiple medications. Polypharmacy may increase the risk of DDIs and decrease patient compliance. DDI may put the patient at risk for serious adverse effects and reduce safety and efficacy of treatment. Chloroquine and Kaletra are metabolized by CYP 450 enzymes. In conclusion, they have a higher potential for drug interaction with CYP 3A4 inducers or inhibitors. The interaction of chloroquine or Kaletra with other QT prolonging agents has been life threatening and it is necessary to monitor the plasma concentration of these drugs. The concomitant use of chloroquine and tamoxifen may enhance the risk of retinopathy. The induction of CYP enzymes by TCZ may reduce the effect of other drugs that are metabolized by these pathways. Concomitant use of TCZ and immunosuppressants such as cyclosporine and adalimumab is contraindicated because this interaction can increase the risk of infection.

DISCLOSURES

The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

H.R. and M.N-V. devised the main conceptual ideas. F.P., S. P-A., and H.R. wrote the initial draft of the manuscript. H.R., F.P., and S.P-A. prepared the figures. M.N-V., T.E-M., and T.A-K. reviewed the manuscript and edited it critically for important intellectual content. M.N-V. supervised the study.

DATA AVAILABILITY STATEMENT

Not applicable.

ORCID

Masoud Nouri-Vaskeh https://orcid.org/0000-0002-6656-0292

REFERENCES

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401-402.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
4. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473.
5. Nouri-Vaskeh M, Khalili N, Sharifi A, et al. Clinical characteristics of fatal cases of COVID-19 in Tabriz, Iran: an analysis of 111 patients. Adv J Emerg Med. 2020. https://doi.org/10.22114/ajem. v10i0.499
6. World Health Organization. World Health Organization: coronavirus disease (COVID-19) Situation dashboard. CEST. https://covid19.who.int. Accessed June 25, 2020
7. Committee GOoNH. Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (fourth trial version to sixth trial version).
8. Nouri-Vaskeh M, Alizadeh L. Fecal transmission in COVID-19: a potential shedding route. J Med Virol. 2020. https://doi.org/10.1002/jmv.25816

9. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhu, China. JAMA. 2020;323(11):1061-1069.

10. Nouri-Vaskeh M, Sharifi A, Khaliil N, Zand R, Sharifi A. Dysneptic and non-dysneptic (silent) hypoxemia in COVID-19: possible neurological mechanism. Clin Neurol Neurosurg. 2020;198:106217.

11. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145.

12. Imanpour H, Rezaee H, Nouri-Vaskeh M. Angiotensin 1–7: a novel strategy in COVID-19 treatment. Adv Pharm Bull. 2020;10(4):488-489.

13. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell Res. 2020;30(3):269-271.

14. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55:105932.

15. Kim JY, Choe PG, Oh Y, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020;35(5):61.

16. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.

17. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990;12(6):1139-1146.

18. Hepatitis C. guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-1492.

19. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444-2451.

20. Dixit N, Perelson A. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63(7–8):832-842.

21. Preston SL, Drusano GL, Glue P, Nash J, Gupta S, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999;43(10):2451-2456.

22. Li X-H, Li S-J, Xu Y, et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: a prospective, randomized, controlled trial. Chin J Integr Med. 2017;23(12):887-892.

23. Borio L, Ingleby T, Peters C, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287(18):2391-2405.

24. Ergonul O. Evidence supports ribavirin use in Crimean-Congo hemorrhagic fever. Int J Infect Dis. 2014;29:296.

25. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016;204(7):268-272.

26. Patil SD, Ngo LY, Glue P, Unadkat JD. Intestinal absorption of ribavirin is preferentially mediated by the Na+–nucleoside purine (N1) transporter. Pharm Res. 1998;15(6):950.

27. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002;36(1):72-74.

28. Peterson D, Van Ermnen A. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Am J Health Syst Pharm. 2017;74(12):888-892.

29. Farhoudi M, Khalili H, Kirimzadeh I, Abbasian L. Associated factors of drug–drug interactions of highly active antiretroviral therapy: report from a referral center. Expert Opin Drug Metab Toxicol. 2015;11(4):471-479.

30. Mira JA, López-Cortés LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther. 2007;12(8):1225.

31. Alvarez D, Dieterich D, Brau N, Moorehead L, Ball L, Sulkowski M. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepatitis. 2006;13(10):683-689.

32. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother. 1995;39(6):1376-1378.

33. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 2008;62(6):1365-1373.

34. Solas C, Pambrun E, Winnock M, et al. Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction? Aids. 2012;26(17):2193-2199.

35. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Reader. 2003(17):344-348.

36. Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet. 2001;357(9270):1802-1803.

37. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38(8):e79-e80.

38. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus–coinfected patients during interferon plus ribavirin–based therapy. J Acquir Immune Defic Syndr. 2005;40(1):47-52.

39. Peyrin-biroulet L, Cadranel JF, Noursbaum JB, et al. Interaction of ribavirin with azathiprine metabolism potentially induces myelo-suppression. Aliment Pharmacol Ther. 2008;28(8):984-993.

40. Gutierrez-Valencia A, Ruiz-Valderas B, Ben-Marzouk-Hidalgo OJ, et al. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. Antimicrob Agents Chemother. 2015;59(6):3257-3262.

41. Garg V, Kauffman RS, Beaumont M, Van Heeswijk R. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17(7):1211.

42. Höner zu Siederdissen C, Maasoumy B, Marra F, et al. Drug–drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561-567.

43. Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. J Clin Pharmacol. 2006;46(5):559-566.

44. Qian Y, Ye X, Du W, et al. A computerized system for detecting signals due to drug–drug interactions in spontaneous reporting systems. Br J Clin Pharmacol. 2010;69(1):67-73.

45. Tanenbaum L, Tuffanelli DL. Antimalarial agents: chloroquine, hydroxychloroquine, and quinacrine. Arch Dermatol. 1980;116(5):587-591.

46. Wallace D. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus. 1996;5(suppl):S9–S4.

47. Okun E, Gouras P, Bernstein H, von Sallmann L. Chloroquine retinopathy: a report of eight cases with ERG and dark-adaptation findings. Arch Ophthalmol. 1963;69(1):59-71.

48. Hughes JT, Esliri M, Oxbury J, Whitty C. Chloroquine myopathy. QJM: Int J Med. 1971;40(1):85-93.

49. Purohit V. Chloroquine neuromyotoxicity. Am J Med. 1988;84(3):568.

50. Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg. 1964;80(4):407-412.
51. Xu C, Zhu L, Chan T, et al. Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci. 2016;105(2):884-890.

52. Nicolas J, Mauduit G, Haond J, Chouvet B, Thivolet J. Severe pioriasis induced by chloroquine (nivaquine). Paper presented at: Annales de Dermatologie et de Venereologie 1988.

53. Guidelines for the prevention D, and treatment, of novel coronavi rus-induced pneumonia Tete. http://www.nhc.gov.cn/zyyjgl/s7653 p/202002/20834a8326dd94d329df351d7da8e9f2/files/b218c feb1bc54639a1277922b6b817.pdf. Accessed February 23, 2020.

54. Hillal-Dandan R, Brunton L. Goodman and Gilman Manual of Pharmacology and Therapeutics, 2. Philadelphia: McGraw Hill Professional; 2013.

55. Kim K-A, Park J-Y, Lee J-S, Lim S. Cytochrome P450 2C8 and chloroquine on paracetamol disposition and kinetics. Br J Clin Pharmacol. 1986;21(3):322-324.

56. McElain J, Mukhtar H, D'arcy P, Temple D, Collier P. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163.

57. Iwugwu M, Alok K. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658.

58. Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol. 1987;27(10):813-816.

59. Ette EI, Brown-Awala EA, Essien EE. Effect of ranitidine on chloroquine disposition. Drug Intell Clin Pharm. 1987;21(9):732-734.

60. Vazquez-Martín J, López-Bonetet E, Cufí S, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Update. 2011;14(4-5):212-223.

61. Farrow JM, Yang JC, Evans CP. Autoaphy as a modulator and target in prostate cancer. Nat Rev Urol. 2014;11(9):508.

62. Carew JS, Medina EC, Esquivel JA II, et al. Autoaphy inhibition enhances vorinostat-induced apoptosis via ubiquitinprotein accumulation. J Cell Mol Med. 2010;14(10):2448-2459.

63. Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608-1621.

64. Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1994;37(6):830-833.

65. Fukritayakamee S, Tarning J, Jittamala P, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58(6):3354-3359.

66. Seideman P, Lindström B. Pharmacokinetic interactions of penicillamine in rheumatoid arthritis. J Rheumatol. 1989;16(4):473-474.

67. Munera Y, Hugues F, Le Jeune C, Pays J. Interaction of thyrroxine sodium with antimalarial drugs. BMJ. 1997;314(7094):1593.

68. Masinirembwa C, Naik Y, Hasler J. The effect of chloroquine on the pharmokinetics and metabolism of praziquantel in rats and in humans. Biopharm Drug Dispos. 1994;15(1):33-43.

69. Achumba JI, Ette EI, Thomas WO, Essien EE. Chloroquine-induced acute dystonic reactions in the presence of metronidazole. Drug Intell Clin Pharm. 1988;22(4):308-310.

70. Cook JA, Randinitis EJ, Bramson CR, Wesche DL. Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg. 2006;74(3):407-412.

71. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol. 2007;47(10):1222-1230.

72. Ali HM. Reduced ampicillin bioavailability following oral co-administration with chloroquine. J Antimicrob Chemother. 1985;15(6):781-784.

73. Finielz P, Gendoo Z, Chuet C, Guiserix J. Interaction between cyclosporin and chloroquine. Nephron. 1993;65(2):333.

74. Landèvre R, Rietveld J, Zwinderman A, Bruyn G, Breedveld F. Dijkmans B. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol. 1998;25(8):1493-1498.

75. Nampoury N, Nessim J, Gupta RK, Johny KV. Drug interaction of chloroquine with ciclosporin. Nephron. 1992;62(1):108-109.

76. Ilo CE, Ezejiofor NA, Agbakoba N, et al. Effect of chloroquine on the urinary excretion of ciprofloxacin. Am J Ther. 2008;15(5):419-422.

77. Ilo E, Orisakwe O, Ilondu N, et al. Effect of chloroquine on the bioavailability of ciprofloxacin in man. J Controlled Release. 2006;2(116):e109-e110.

78. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386-1394.

79. Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol. 2008;127(2):e80-e82.

80. Al-Bari M, Islam M. Clinically significant drug interaction profiles of chloroquine analogues with adverse consequences and risk management. J Sci Res. 2015;7(3):177-195.

81. Lewis J, Gregorian T, Portillo I, Goad J. Drug interactions with antimalarial medications in older travelers: a clinical guide. J Travel Med. 2020;27(1):tao089.

82. Lancaster D, Adio R, Tai K, et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol. 1990;42(4):267-271.

83. Rengelshausen J, Burhenne J, Fröhlich M, et al. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol. 2004;60(10):709-715.

84. Onyeji CO, Toriola TA, Ogunbona FA. Lack of pharmacokinetic interaction between chloroquine and imipramine. Ther Drug Monit. 1993;15(1):43-46.

85. Obua C, Ntale M, Lundblad M, et al. Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. AFR Health Sci. 2006;6(2):86-92.

86. Neuvonen P, Kivistö K, Laine K, Pyykkö K. Prevention of chloroquine absorption by activated charcoal. Hum Exp Toxicol. 1992;11(2):117-120.

87. Li X, He Z, Chen L, et al. Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. Parasitol Res. 2011;109(6):1519-1524.

88. Miller AK, Harrell E, Y, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013;76(6):858-867.

89. Chandwan J, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023.

90. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338(18):1281-1293.

91. Sakuma S, Matsumoto S, Ishizuka N, et al. Enhanced boosting of oral absorption of lopinavir through electrospary coencapsulation with ritonavir. J Pharm Sci. 2015;104(9):2977-2985.

92. Crommentuyn KM, Mulder JW, Mairuhu A, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9(5):779-786.

93. Barlow A, Landolf KM, Barlow B, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020. https://doi.org/10.1002/phar.2398
95. Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79.

96. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

97. Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020. https://doi.org/10.1016/j.medj.2020.04.001

98. Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. Role of Lopinavir/Ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives. J Clin Med. 2020;9(7):2050.

99. Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329-1352.

100. Stolbach A, Paziana K, Heverling H, Pham P. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326-341.

101. Giguère P, Nhean S, Tseng A, Hughes CA, Angel JB. Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications. Can J Cardiol. 2019;35(3):326-340.

102. Chauvin B, Drouot S, Barrail-Tran A, Taburet A-M. Drug–rheumatology interaction: role of corticosteroids. CNS Spectr. 2010;15(6):587-598.

103. Bastida C, Also M, Pericas J, Letang E, Tuset M, Miró J. Tocilizumab and antiretroviral agents. Expert Opin Drug Saf. 2010;9(5):723-742.

104. Rattanapunya S, Cressey TR, Rueangweerayut R, Tawon Y, Carvalho EM, Mähner M, et al. A comparison of tocilizumab with abatacept for the treatment of rheumatoid arthritis in patients with inadequate response to traditional disease-modifying antirheumatic drugs: a randomized trial in patients with rheumatoid arthritis and rheumatoid arthritis subtypes via effects on CYP-mediated drug clearance. J Health-Syst Pharm. 2015;60(10):457-466.

105. Soyinka JO, Onyeji CO, Omoruyi SI, Wosilat AR, Bice EW, Read JR, et al. Effect of tocilizumab on immune response to COVID-19 in healthy volunteers following concurrent administration of tocilizumab and hydroxychloroquine. Br J Clin Pharmacol. 2020;90(1):262-270.

106. Goodlet KJ, Zmarlicky MT, Peckham AM. Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. CNS Spectr. 2019;24(3):287-312.

107. Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf. 2010;9(5):723-742.

108. Nørgaard BL, Rise P, Pedersen O, Jørgensen N, Hviid A. Antiretroviral and antifungal drug interactions: an analysis of the Danish ARV register. AIDS. 2012;26:S39-S53.

109. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug study. Arthritis Rheum. 2008;58(10):2968-2980.

110. Hoeltzlein E, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Paper presented at: Seminars in arthritis and rheumatism 2016.

111. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013;15(2):88-95.

112. Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF T cells and inflammatory CD4+ and CD8+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv. 2020. https://doi.org/10.1101/2020.02.12.945576

113. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020. https://doi.org/10.1073/pnas.2005615117

114. Roche PA. RoActemra 20 mg/mL concentrate for solution for infusion. EU summary of product characteristics 2020.

115. Coutant DE, Hall SD. Disease-drug interactions in inflammatory status via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2016;57(7):849-863.

116. Sánchez JD, Hernández MV, Sannotti M. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(9):1089-1103.
133. Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. *Ther Drug Monit*. 2020. https://doi.org/10.1097/TFD.0000000000000761

134. Catherine Marcucci M, Sandson NB, Gierl BT. *Safety and Drug-Drug Interaction Considerations for Double Concentrated 2% Propofol*. Rochester, MN: The Anesthesia Patient Safety Foundation; 2020.

135. Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to human clinical trials for treatment of COVID-19. *ACS Cent Sci*. 2020. https://doi.org/10.1021/acscentsci.0c00489

136. Alhazzani W, Møller MH, Arabi YM, et al. COVID-19. *Intensive Care Med*. 2019;2020:1-34.

137. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J Biol Chem*. 2020;295(15):4773-4779.

138. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med*. 2017;9(396). https://doi.org/10.1126/scitranslmed.aal3653

139. Bardon VF, Salomon LJ, Leruez-Ville M, Ville Y. How should we treat pregnant women infected with SARS-CoV-2? *BJOG*. 2020. https://doi.org/10.1111/1471-0528.16270

140. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. *N Engl J Med*. 2020;382:2327-2336.

141. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020. https://doi.org/10.1016/S0140-6736(20)31022-9

How to cite this article: Rezaee H, Pourkarim F, Pourtaghi-Anvarian S, Entezari-Maleki T, Asvadi-Kermani T, Nouri-Vaskeh M. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. *Pharmacol Res Perspect*. 2021;9:e00705. https://doi.org/10.1002/prp2.705